Eli BenDavid

Dr. Eli BenDavid

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Frontiers in Genome Editing
Verified
Journal Article
Open access
YLYaoyao Lu
Yaoyao Lu
CMCedric Happi Mbakam
Cedric Happi Mbakam
Bo SongBo Song
Bo Song
EBEli BenDavid
Eli BenDavid
Jacques P. TremblayJacques P. Tremblay
Jacques P. Tremblay
Advancements in genome editing make possible to exploit the functions of enzymes for efficient DNA modifications with tremendous potential to treat human genetic diseases. Several nuclease genome editing strategies including Meganucleases (MNs), Zinc Finger Nucleases (ZFNs), Transcription Activator-like Effector Nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated proteins (CRISPR-Cas) have been developed for the correction of genetic mutations. CRISPR-Cas has further been engineered to create nickase genome editing tools including Base editors and Prime editors with much precision and efficacy. In this review, we summarized recent improvements in nuclease and nickase genome editing approaches for the treatment of genetic diseases. We also highlighted some limitations for the translation of these approaches into clinical applications.

11 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBEli BenDavid
Eli BenDavid
SRSina Ramezanian
Sina Ramezanian
YLYaoyao Lu
Yaoyao Lu
JRJoël Rousseau
Joël Rousseau
ASAvi Schroeder
Avi Schroeder
Jacques P. TremblayJacques P. Tremblay
Jacques P. Tremblay
Prime editing shows potential as a precision genome editing technology, as well as the potential to advance the development of next-generation nanomedicine for addressing neurological disorders. However, turning in prime editors (PEs), which are macromolecular complexes composed of CRISPR/Cas9 nickase fused with a reverse transcriptase and a prime editing guide RNA (pegRNA), to the brain remains a considerable challenge due to physiological obstacles, including the blood–brain barrier (BBB). This review article offers an up-to-date overview and perspective on the latest technologies and strategies for the precision delivery of PEs to the brain and passage through blood barriers. Furthermore, it delves into the scientific significance and possible therapeutic applications of prime editing in conditions related to neurological diseases. It is targeted at clinicians and clinical researchers working on advancing precision nanomedicine for neuropathologies.